Related Experiment Video
Updated: Aug 16, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Brandon M Huffman1, Haley Ellis1, Alexander C Jordan1
1Division of Gastrointestinal Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Abstract:
The aggressive biology of pancreatic ductal adenocarcinoma (PDAC), along with its limited sensitivity to many systemic therapies, presents a major challenge in the management of patients with metastatic PDAC. Over the past decade, the incorporation of combinatorial cytotoxic chemotherapy regimens has improved patient outcomes. Despite these advances, resistance to cytotoxic chemotherapy inevitably occurs, and there is a great need for effective therapies. A major focus of research has been to identify molecularly defined subpopulations of patients with PDAC who may benefit from targeted therapies that are matched to their molecular profile. Recent successes include the demonstration of the efficacy of maintenance PARP inhibition in PDAC tumors harboring deleterious BRCA1, BRCA2, and PALB2 alterations. In addition, while therapeutic targeting of KRAS was long thought to be infeasible, emerging data on the efficacy of KRAS G12C inhibitors have increased optimism about next-generation KRAS-directed therapies in PDAC. Meanwhile, KRAS wild-type PDAC encompasses a unique molecular subpopulation of PDAC that is enriched for targetable genetic alterations, such as oncogenic BRAF alterations, mismatch repair deficiency, and FGFR2, ALK, NTRK, ROS1, NRG1, and RET rearrangements. As more molecularly targeted therapies are developed, precision medicine has the potential to revolutionize the treatment of patients with metastatic PDAC.
Insights
Pancreatic ductal adenocarcinoma (PDAC) treatment faces challenges due to aggressive biology and therapy resistance. Precision medicine offers new hope by targeting specific molecular alterations in PDAC patients for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is aggressive and often resistant to standard therapies.
- While chemotherapy has improved outcomes, resistance remains a significant clinical challenge.
- Identifying molecularly defined patient subgroups is crucial for developing effective targeted treatments.
Purpose of the Study:
- To review recent advances in precision medicine for metastatic PDAC.
- To highlight emerging targeted therapies based on specific molecular profiles.
- To discuss the potential of precision medicine to revolutionize PDAC treatment.
Main Methods:
- Review of recent clinical successes and emerging research in PDAC targeted therapy.
- Analysis of molecular alterations and their corresponding targeted treatments.
- Focus on specific genetic alterations like BRCA, PALB2, KRAS, and others.
Main Results:
- PARP inhibition shows efficacy in PDAC with BRCA1/2 and PALB2 alterations.
- KRAS G12C inhibitors demonstrate promise, reviving KRAS-directed therapy development.
- KRAS wild-type PDAC exhibits targetable alterations including BRAF, MMR deficiency, and various gene rearrangements.
Conclusions:
- Precision medicine, guided by molecular profiling, holds significant potential for treating metastatic PDAC.
- Targeted therapies are increasingly effective against specific molecular subtypes of PDAC.
- Continued development of molecularly targeted agents is key to advancing PDAC patient care.
